120 related articles for article (PubMed ID: 29311111)
1. Dual Blockade of Interleukin-1
Ruzek MC; Huang L; Zhang TT; Bryant S; Slivka PF; Cuff CA; Tripp C; Blaich G
J Pharmacol Exp Ther; 2018 Mar; 364(3):474-484. PubMed ID: 29311111
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.
Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D
Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345
[TBL] [Abstract][Full Text] [Related]
3. The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway.
Wu Q; Wang Y; Wang Q; Yu D; Wang Y; Song L; Liu Z; Ye X; Xu P; Cao H; Li D; Ren G
Immunol Lett; 2016 Nov; 179():68-79. PubMed ID: 27616043
[TBL] [Abstract][Full Text] [Related]
4. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A.
Zheng S; Shen F; Jones B; Fink D; Geist B; Nnane I; Zhou Z; Hall J; Malaviya R; Ort T; Wang W
MAbs; 2020; 12(1):1770018. PubMed ID: 32544369
[TBL] [Abstract][Full Text] [Related]
5. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
[TBL] [Abstract][Full Text] [Related]
6. A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis.
Qi J; Kan F; Ye X; Guo M; Zhang Y; Ren G; Li D
Int Immunopharmacol; 2012 Dec; 14(4):770-8. PubMed ID: 23092552
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model.
Li Q; Ren G; Xu L; Wang Q; Qi J; Wang W; Zhou B; Han X; Sun C; Wu Q; Yu Y; Peng Z; Zheng S; Li D
Int Immunopharmacol; 2014 Jul; 21(1):119-27. PubMed ID: 24800661
[TBL] [Abstract][Full Text] [Related]
8. Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A.
Shan Y; Shi K; Qian X; Chang Z; Yang J; Gao Y; Jin W; Luo Q; Xu Q
Biochem Biophys Res Commun; 2019 Sep; 517(2):303-309. PubMed ID: 31353088
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
Chao CC; Chen SJ; Adamopoulos IE; Davis N; Hong K; Vu A; Kwan S; Fayadat-Dilman L; Asio A; Bowman EP
Autoimmunity; 2011 May; 44(3):243-52. PubMed ID: 20925596
[TBL] [Abstract][Full Text] [Related]
10. A recombinant IgG-like bispecific antibody acting as interleukin-1β and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis.
Wang Y; Wu Q; Liu Z; Guo X; Zhou L; Wang Y; Song L; Wang N; Zheng Q; Wang W; Ren G; Li D
Biomed Pharmacother; 2017 May; 89():426-437. PubMed ID: 28249243
[TBL] [Abstract][Full Text] [Related]
11. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
[TBL] [Abstract][Full Text] [Related]
12. The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.
Biscetti F; Flex A; Pecorini G; Angelini F; Arena V; Stigliano E; Gremese E; Tolusso B; Ferraccioli G
Clin Exp Immunol; 2016 Apr; 184(1):62-72. PubMed ID: 26671547
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.
Othman AA; Khatri A; Loebbert R; Peloso PM
Clin Pharmacol Drug Dev; 2019 May; 8(4):492-502. PubMed ID: 30156758
[TBL] [Abstract][Full Text] [Related]
15. Interleukin (IL)-17A, F and AF in inflammation: a study in collagen-induced arthritis and rheumatoid arthritis.
Sarkar S; Justa S; Brucks M; Endres J; Fox DA; Zhou X; Alnaimat F; Whitaker B; Wheeler JC; Jones BH; Bommireddy SR
Clin Exp Immunol; 2014 Sep; 177(3):652-61. PubMed ID: 24813051
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice.
Shen F; Verma AH; Volk A; Jones B; Coleman BM; Loza MJ; Malaviya R; Moore B; Weinstock D; Elloso MM; Gaffen SL; Ort T
J Immunol; 2019 Apr; 202(7):2017-2026. PubMed ID: 30745461
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody.
Chen W; Kong Y; Li W; Zhou Y; Wu M; Chen T; Wu Y; Qiao H; Qiu Z; Qiu J
Protein Expr Purif; 2021 Nov; 187():105950. PubMed ID: 34363980
[TBL] [Abstract][Full Text] [Related]
18. Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance.
Zwerina K; Koenders M; Hueber A; Marijnissen RJ; Baum W; Heiland GR; Zaiss M; McLnnes I; Joosten L; van den Berg W; Zwerina J; Schett G
Eur J Immunol; 2012 Feb; 42(2):413-23. PubMed ID: 22101928
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis.
Qi J; Ye X; Ren G; Kan F; Zhang Y; Guo M; Zhang Z; Li D
Mol Immunol; 2014 Feb; 57(2):59-65. PubMed ID: 24091292
[TBL] [Abstract][Full Text] [Related]
20. Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models.
Liu Z; Song L; Yang J; Liu H; Zhang Y; Pi X; Yan Y; Chen H; Yu D; Yin C; Liu T; Li X; Zhang C; Li D; Wang Z; Xiao W
Int Immunopharmacol; 2024 Jul; 136():112383. PubMed ID: 38843642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
